Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Replimune Group downgraded to Neutral from Buy at H.C. Wainwright » 06:14
07/01/20
07/01
06:14
07/01/20
06:14
REPL

Replimune Group

$24.81 /

-0.19 (-0.76%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns downgraded Replimune Group to Neutral from Buy with an unchanged price target of $25. The analyst believes the shares are currently fairly priced and recommends taking profits following the recent rally.

ShowHide Related Items >><<
REPL Replimune Group
$24.81 /

-0.19 (-0.76%)

REPL Replimune Group
$24.81 /

-0.19 (-0.76%)

06/04/20 BMO Capital
Replimune Group price target raised to $40 from $31 at BMO Capital
06/04/20 Barclays
Replimune Group price target raised to $25 from $21 at Barclays
06/03/20 BMO Capital
BMO Capital says weakness in Replimune a 'buying opportunity'
05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
REPL Replimune Group
$24.81 /

-0.19 (-0.76%)

  • 09
    Jun
  • 14
    Nov
Over a week ago
Syndicate
Replimune Group 2.826M share Spot Secondary priced at $23.00 » 06:31
06/09/20
06/09
06:31
06/09/20
06:31
REPL

Replimune Group

$24.06 /

+1.12 (+4.88%)

The deal size was…

The deal size was increased to $100M in common stock from $80M in common stock and the price range was $22.50-$23.00. JPMorgan, SVB Leerink and BMO Capital acted as joint book running managers for the offering.

ShowHide Related Items >><<
REPL Replimune Group
$24.06 /

+1.12 (+4.88%)

REPL Replimune Group
$24.06 /

+1.12 (+4.88%)

06/04/20 BMO Capital
Replimune Group price target raised to $40 from $31 at BMO Capital
06/04/20 Barclays
Replimune Group price target raised to $25 from $21 at Barclays
06/03/20 BMO Capital
BMO Capital says weakness in Replimune a 'buying opportunity'
05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
REPL Replimune Group
$24.06 /

+1.12 (+4.88%)

  • 09
    Jun
Syndicate
Replimune Group $80M Spot Secondary; price range $22.50-$23.00 » 16:25
06/08/20
06/08
16:25
06/08/20
16:25
REPL

Replimune Group

$23.85 /

+0.91 (+3.97%)

JPMorgan, SVB Leerink and…

JPMorgan, SVB Leerink and BMO Capital are acting as joint book running managers for the offering.

ShowHide Related Items >><<
REPL Replimune Group
$23.85 /

+0.91 (+3.97%)

REPL Replimune Group
$23.85 /

+0.91 (+3.97%)

06/04/20 BMO Capital
Replimune Group price target raised to $40 from $31 at BMO Capital
06/04/20 Barclays
Replimune Group price target raised to $25 from $21 at Barclays
06/03/20 BMO Capital
BMO Capital says weakness in Replimune a 'buying opportunity'
05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
REPL Replimune Group
$23.85 /

+0.91 (+3.97%)

Syndicate
Replimune Group announces offering of $80M of common stock, warrants » 16:21
06/08/20
06/08
16:21
06/08/20
16:21
REPL

Replimune Group

$23.85 /

+0.91 (+3.97%)

Replimune Group announced…

Replimune Group announced a proposed public offering of $80M of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. J.P. Morgan Securities, SVB Leerink, and BMO Capital Markets are acting as joint book-running managers for the proposed offering. Wedbush Securities is acting as lead manager for the proposed offering.

ShowHide Related Items >><<
REPL Replimune Group
$23.85 /

+0.91 (+3.97%)

REPL Replimune Group
$23.85 /

+0.91 (+3.97%)

06/04/20 BMO Capital
Replimune Group price target raised to $40 from $31 at BMO Capital
06/04/20 Barclays
Replimune Group price target raised to $25 from $21 at Barclays
06/03/20 BMO Capital
BMO Capital says weakness in Replimune a 'buying opportunity'
05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
REPL Replimune Group
$23.85 /

+0.91 (+3.97%)

Over a month ago
Recommendations
Replimune Group price target raised to $40 from $31 at BMO Capital » 09:01
06/04/20
06/04
09:01
06/04/20
09:01
REPL

Replimune Group

$20.10 /

+0.12 (+0.60%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim raised the firm's price target on Replimune Group to $40 from $31 and keeps an Outperform rating on the shares after its RP1 data update from its Phase 2 cohorts in Melanoma and Non-Melanoma skin cancer. The analyst notes that his CSCC probability of success increases to 65% from 40% and sees RP1 adding meaningful benefit to anti-PD-1 therapy while supporting multiple accelerated paths to market.

ShowHide Related Items >><<
REPL Replimune Group
$20.10 /

+0.12 (+0.60%)

REPL Replimune Group
$20.10 /

+0.12 (+0.60%)

06/04/20 Barclays
Replimune Group price target raised to $25 from $21 at Barclays
06/03/20 BMO Capital
BMO Capital says weakness in Replimune a 'buying opportunity'
05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
REPL Replimune Group
$20.10 /

+0.12 (+0.60%)

Recommendations
Replimune Group price target raised to $25 from $21 at Barclays » 06:29
06/04/20
06/04
06:29
06/04/20
06:29
REPL

Replimune Group

$20.10 /

+0.12 (+0.60%)

Barclays analyst Peter…

Barclays analyst Peter Lawson raised the firm's price target on Replimune Group to $25 from $21 and keeps an Overweight rating on the shares. After speaking with management, the analyst is encouraged with "deepening of responses" for RP1 plus nivolumab in cutaneous squamous cell carcinoma.

ShowHide Related Items >><<
REPL Replimune Group
$20.10 /

+0.12 (+0.60%)

REPL Replimune Group
$20.10 /

+0.12 (+0.60%)

06/03/20 BMO Capital
BMO Capital says weakness in Replimune a 'buying opportunity'
05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
REPL Replimune Group
$20.10 /

+0.12 (+0.60%)

Recommendations
BMO Capital says weakness in Replimune a 'buying opportunity' » 10:44
06/03/20
06/03
10:44
06/03/20
10:44
REPL

Replimune Group

$19.62 /

-0.36 (-1.80%)

BMO Capital analyst Do…

BMO Capital analyst Do Kim reiterated an Outperform rating and $31 price target on Replimune Group, calling the weakness in shares following the RP1 Phase 2 update a "buying opportunity." The analyst believes the data "remains solid" and noted that while the stock might be "under pressure due to refractory melanoma responses slipping or discontinuation of the bladder cancer cohort," Kim said neither have meaningful impact to his confidence in RP1.

ShowHide Related Items >><<
REPL Replimune Group
$19.62 /

-0.36 (-1.80%)

REPL Replimune Group
$19.62 /

-0.36 (-1.80%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
REPL Replimune Group
$19.62 /

-0.36 (-1.80%)

Hot Stocks
Replimune Group 'on track' to initiate Phase 1 trial of RP3 in 2020 » 07:25
06/03/20
06/03
07:25
06/03/20
07:25
REPL

Replimune Group

$19.98 /

+0.2 (+1.01%)

The Phase 1 clinical…

The Phase 1 clinical trial of RP3 alone and in combination with anti-PD-1 therapy remains on track to initiate in 2020.

ShowHide Related Items >><<
REPL Replimune Group
$19.98 /

+0.2 (+1.01%)

REPL Replimune Group
$19.98 /

+0.2 (+1.01%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
REPL Replimune Group
$19.98 /

+0.2 (+1.01%)

Hot Stocks
Replimune Group expects inital data from Phase 1 trial of RP2 by end of 2020 » 07:25
06/03/20
06/03
07:25
06/03/20
07:25
REPL

Replimune Group

$19.98 /

+0.2 (+1.01%)

The ongoing Phase 1…

The ongoing Phase 1 clinical trial evaluating the safety, tolerability, and optimal dose for further development of RP2 alone and in combination with Opdivo remains on track, with initial safety and efficacy data from the single agent RP2 part of the clinical trial together with initial data in combination with Opdivo expected to be presented by the end of 2020.

ShowHide Related Items >><<
REPL Replimune Group
$19.98 /

+0.2 (+1.01%)

REPL Replimune Group
$19.98 /

+0.2 (+1.01%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
REPL Replimune Group
$19.98 /

+0.2 (+1.01%)

Conference/Events
Replimune Group to hold a conference call » 07:25
06/03/20
06/03
07:25
06/03/20
07:25
REPL

Replimune Group

$19.98 /

+0.2 (+1.01%)

Management holds a…

Management holds a conference call to provide an update on Phase 1/2 Clinical Data on patients with melanoma and non-melanoma skin cancers on June 3 at 8 am. Webcast Link

ShowHide Related Items >><<
REPL Replimune Group
$19.98 /

+0.2 (+1.01%)

REPL Replimune Group
$19.98 /

+0.2 (+1.01%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
REPL Replimune Group
$19.98 /

+0.2 (+1.01%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.